Improvement of Blood Lipids, Glucose Tolerance and Insulin Sensitivity

BACKGROUND OF THE INVENTION

Resistant starch (RS) is defined as the sum of starch and starch digestion products that are not digested in the small intestine but instead reach the large intestine as a fermentable fiber substrate. Previous research has established RS as an effective dietary prebiotic supplement to modulate intestinal function and improve systemic health in both animals and humans. In human health and disease prevention, RS has potential application in weight management, the treatment of gastrointestinal disorders, and the improvement of blood lipids, glucose tolerance and insulin sensitivity [1, 2].

It is important to note however that all resistant starch is not equal. Specifically, there is exceptional diversity encountered among RS varieties. Specifically, RS varieties originating from different plant sources and manufactured with alternative processing technologies will possess unique physiochemical properties.

Although dietary guidelines recommend a daily dietary fiber intake of 25-35 g, it is clear that fiber consumption amongst Canadians is low. Canadians consume between 3-8 g of RS per day, partly due to the variability of RS content in common foods and a general lack of commercially available RS-enriched foods and nutraceutical products.

In order for dietary fibers such as RS to have a significant and sustained public health impact, there is a need to develop novel strategies to increase dietary fiber intake. Development of a RS capsule may be a convenient and effective approach to increase RS consumption and improve human health. Surprisingly, there are currently no such commercially available RS-based fiber capsules available within Canada.

SUMMARY OF THE INVENTION

According to one embodiment of the invention, there is provided a method of increasing High Density Lipoprotein plasma levels in an individual in need of such treatment comprising administering to said individual an effective amount of resistant potato starch. Preferably, the resistant potato starch is MSPrebiotic® Resistant Potato Starch.

In another embodiment of the invention, there is provided use of resistant potato starch to increase High Density Lipoprotein plasma levels in an individual in need of such treatment. Preferably, the resistant potato starch is MSPrebiotic® Resistant Potato Starch.

In yet another embodiment of the invention, there is provided use of resistant potato starch in the preparation of a medicament for increasing High Density Lipoprotein plasma levels in an individual in need of such treatment. Preferably, the resistant potato starch is MSPrebiotic® Resistant Potato Starch.

For example, in these embodiments, an individual in need of such treatment may be an individual with a fasting HDL plasma level below 40 mg/dL or below 1 mmol/L or an individual with a fasting LDL to HDL ratio of greater than 5 or an individual with high fasting LDL levels combined with low fasting HDL levels or an individual with a familial history of cardiovascular disease or who is otherwise considered to be at risk of developing cardiovascular disease.

According to one embodiment of the invention, there is provided a method of decreasing blood glucose levels in an individual in need of such treatment comprising administering to said individual an effective amount of resistant potato starch. Preferably, the resistant potato starch is MSPrebiotic® Resistant Potato Starch.

In another embodiment of the invention, there is provided use of resistant potato starch to decrease blood glucose levels in an individual in need of such treatment. Preferably, the resistant potato starch is MSPrebiotic® Resistant Potato Starch.

In yet another embodiment of the invention, there is provided use of resistant potato starch in the preparation of a medicament for decreasing blood glucose levels in an individual in need of such treatment. Preferably, the resistant potato starch is MSPrebiotic® Resistant Potato Starch.

As will be appreciated by one of skill in the art, an individual in need of such treatment in these embodiments may be for example an individual who has or is at risk of having a blood glucose level outside the normal range, that is, greater than between 70 and 100 mg/dL, or greater than 100 mg/dL. Alternatively, the individual may be an individual who has diabetes and who has or is suspected of having or is at risk of having a blood glucose range for outside of 70-130 mg/dL or greater than 130 mg/dL before meals and less than 180 mg/dL after meals. Alternatively, the individual in need of such treatment may be hyperglycemic or chronically hyperglycemic or may be diabetic. Preferably, the individual is a human.

According to one embodiment of the invention, there is provided a method of decreasing insulin resistance in an individual in need of such treatment comprising administering to said individual an effective amount of resistant potato starch. Preferably, the resistant potato starch is MSPrebiotic® Resistant Potato Starch.

In another embodiment of the invention, there is provided use of resistant potato starch to decrease insulin resistance in an individual in need of such treatment. Preferably, the resistant potato starch is MSPrebiotic® Resistant Potato Starch.

In yet another embodiment of the invention, there is provided use of resistant potato starch in the preparation of a medicament for decreasing insulin resistance in an individual in need of such treatment. Preferably, the resistant potato starch is MSPrebiotic® Resistant Starch.

For example, in these embodiments, an individual in need of such treatment may be an individual with increased insulin resistance, for example an individual with Type 2 diabetes or a person with a familial history of Type 2 diabetes or a person at risk of developing Type 2 diabetes.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1: Time course of body weight gain (lbs).

FIG. 2: Blood Lipid Response (mmol/L).

FIG. 3: HDL Particle Number (μmol/L).

FIG. 4: Blood glucose (% change)

FIG. 5: Blood insulin (μIU/mL)

FIG. 6: HOMA-IR

FIG. 7: VLDL Particle Number (nmol/L)

FIG. 8: Total LDL Particle Number (nmol/L)

FIG. 9: Lipoprotein Particle Size (nm)

DESCRIPTION OF THE PREFERRED EMBODIMENTS

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned hereunder are incorporated herein by reference.

MSP Starch Products Inc., manufactures MSPrebiotic® Resistant Potato Starch, a native, unmodified RS type 2 preparation of food grade quality for animal and human food application.

In order to evaluate the potential application of MSPrebiotic® Resistant Potato Starch as a novel health promoting fiber vehicle in the human nutraceutical industry, a pre-clinical examination of the metabolic health benefits of a novel MSPrebiotic® Resistant Potato Starch capsule in a domestic pig model fed a typical Western diet was undertaken.

Previous research in both humans and biomedical animal models suggests that resistant starch consumption may have potential application in weight management, the improvement of blood lipids, glucose tolerance and insulin sensitivity. However, clinical research also suggests that there is significant variability in the health promoting responses to RS consumption, partly due to the exceptional diversity that is encountered among RS varieties, as discussed herein.

The objective of this pre-clinical study was to access the metabolic responses to a novel MSPrebiotic® Resistant Potato Starch capsule in a pig model. Twelve 8-week old male Yorkshire pigs were randomly assigned to two groups: 1) a placebo group supplemented with capsules containing normal gelatinized starch; or 2) a RS group supplemented with RS capsules containing MSPrebiotic® Resistant Potato Starch at a dose of 10 g/d.

As discussed below, compared with the placebo group, MSPrebiotic® Resistant Potato Starch supplementation increased (p<0.05) plasma total HDL-particles (28%) and reduced blood glucose (−11%) and insulin resistance (−54%) as estimated by HOMA-IR.

High-Density Lipoprotein (HDL) is one of the five major groups of lipoproteins. Specifically, HDL is the smallest of the lipoprotein particles and transports cholesterol primarily to the liver. Furthermore, increasing one's HDL levels has been found to improve cardiovascular health. Specifically, individuals with low HDL-C levels, for example, lower than 40 mg/dL or about 1 mmol/L or individuals who have a ratio of LDL-C (Low Density Lipoprotein) to HDL-C of 5 or greater are considered to be at greater risk of developing cardiovascular diseases.

As discussed below, MSPrebioitc® Resistant Potato Starch has been shown to increase the total number of HDL-particles in plasma compared to a control of similar age and fed an otherwise substantially similar diet by 28%.

Consequently, an effective amount of resistant potato starch, for example, MSPrebiotic® Resistant Potato Starch, can be administered to an individual in need of such treatment to increase HDL particle number. Preferably, the individual is a human.

Accordingly, in one embodiment of the invention, there is provided a method of increasing High Density Lipoprotein plasma levels in an individual in need of such treatment comprising administering to said individual an effective amount of resistant potato starch. Preferably, the resistant potato starch is MSPrebiotic® Resistant Potato Starch.

As will be appreciated by one of skill in the art, the increase in HDL particle number or HDL plasma level in the individual may be in comparison to the HDL particle number or HDL plasma level in said individual prior to beginning administration or treatment. Alternatively, the increase may be in comparison to an untreated control of similar age and condition. As will be appreciated by one of skill in the art, the control does not necessarily need to be repeated every time.

Furthermore, the effective amount may vary according to many different factors, for example, the age, weight, and/or condition of the individual. It is of note that the appropriate effective amount for a given individual can be easily determined through routine experimentation.

For illustrative purposes, an “effective amount”, particularly for humans, may be 0.25 grams to 40 grams of MSPrebioitc® Resistant Potato Starch. Alternatively, an effective amount may be 0.5 grams to 40 grams or 0.25 grams to 30 grams or 0.5 grams to 30 grams.

As will be appreciated by one of skill in the art, the “effective amount” may be taken on a regular schedule or regimen, for example, once per day or every other day.

It is important to note that the “effective amount” does not need to be taken in a single dose and may be taken in multiple or partial doses throughout the day, as discussed herein.

For example, convenient dosages of resistant starch include but are by no means limited to for example 250 mg capsules or tablets, 500 mg capsules or tablets, a teaspoon of resistant starch, a tablespoon of resistant starch and the like. As will be known by those of skill in the art, a “teaspoon” is typically considered to correspond to approximately 5 grams while a tablespoon is considered to correspond to approximately 10 grams. The resistant starch may be in the form of a powder. Other suitable dosages will be readily apparent to one of skill in the art.

It is noted that in some embodiments, the “effective amount” may be for example one or more teaspoon(s) of MSPrebioitc® Resistant Potato Starch, for example, one, two, three or four teaspoon(s) MSPrebioitc® Resistant Potato Starch. In some embodiments, this dosage may be taken on a regular schedule or regime, for example, once per day, twice per day, three times per day, four times per day, every other day or as needed or desired.

In yet other embodiments, the “effective amount” may be for example one or more tablespoon(s) of MSPrebioitc® Resistant Potato Starch, for example, one, two or three tablespoon(s) MSPrebioitc® Resistant Potato Starch. In some embodiments, this dosage may be taken on a regular schedule or regime, for example, once per day, twice per day, three times per day, four times per day, every other day or as needed or desired.

As discussed herein, other forms of resistant starch may be used within the invention, provided the product or medicament comprising the resistant starch, for example resistant potato starch, for example MSPrebiotic® Resistant Potato Starch, is high in resistant starch. As used herein, a starch that has “high” resistant starch content is a starch that is at least 60% resistant starch.

Accordingly, in the embodiments discussed herein, the resistant potato starch used in the embodiments of the invention is at least 60% resistant potato starch.

Yet further, the inventors have discovered that a key aspect in maintaining the integrity of the resistant starch, that is maintain the starch as a high resistant starch is maintaining the starch at a temperature below 60 C. As will be apparent to one of skill in the art, this includes production of the resistant starch itself and also preparation of medicaments such as tablets and capsules and functional foods and/or beverages to which the resistant starch is added.

In yet another embodiment of the invention, there is provided use of MSPrebiotic® Resistant Potato Starch in the preparation of a medicament for increasing High Density Lipoprotein plasma levels in an individual in need of such treatment.

In yet another embodiment of the invention, there is provided use of MSPrebiotic® Resistant Potato Starch in the preparation of a medicament for reducing the risk of cardiovascular disease in an individual in need of such treatment.

The blood sugar concentration or blood glucose level is the amount of glucose present in blood. The mean normal level in humans is about 5.5 mM (5.5 mmol/L or 100 mg/dL). The normal blood glucose level for non-diabetics should be between 70 and 100 mg/dL. The blood glucose target range for diabetics should be 70-130 mg/dL before meals and less than 180 mg/dL after eating. Blood sugar levels that are persistently high are referred to as hyperglycemic and diabetes is characterized by persistent hyperglycemia.

As discussed herein, the treatment group fed MSPrebiotic® Resistant Potato Starch demonstrated reduced blood glucose (−11%) compared to a control of similar age and fed an otherwise substantially similar diet.

Consequently, an effective amount of resistant potato starch, for example, MSPrebiotic® Resistant Potato Starch can be administered to an individual in need of such treatment to decrease blood glucose.

Accordingly, in one embodiment of the invention, there is provided a method of decreasing blood glucose levels in an individual in need of such treatment comprising administering to said individual an effective amount of resistant potato starch. Preferably, the resistant potato starch is MSPrebiotic® Resistant Potato Starch.

As will be appreciated by one of skill in the art, the decrease in blood glucose levels in the individual may be in comparison to the glucose levels in said individual prior to beginning administration or treatment. Alternatively, the decrease may be in comparison to an untreated control of similar age and condition. As will be appreciated by one of skill in the art, the control does not necessarily need to be repeated every time.

In another embodiment of the invention, there is provided use of resistant potato starch, for example, MSPrebiotic® Resistant Potato Starch, to decrease blood glucose levels in an individual in need of such treatment.

In yet another embodiment of the invention, there is provided use of MSPrebiotic® Resistant Potato Starch in the preparation of a medicament for decreasing blood glucose levels in an individual in need of such treatment.

In yet another embodiment of the invention, there is provided use of MSPrebiotic® Resistant Potato Starch in the preparation of a medicament for treating diabetes in an individual in need of such treatment.

As will be appreciated by one of skill in the art, an individual in need of such treatment may be for example an individual who has or is at risk of having a blood glucose level outside the normal range, that is, greater than between 70 and 100 mg/dL, or greater than 100 mg/dL. Alternatively, the individual may be an individual who has diabetes and who has or is suspected of having or is at risk of having a blood glucose range for outside of 70-130 mg/dL or greater than 130 mg/dL before meals and less than 180 mg/dL after meals. Alternatively, the individual in need of such treatment may be hyperglycemic or chronically hyperglycemic or may be diabetic. Preferably, the individual is a human.

Insulin resistance is a physiological condition in which cells fail to respond to the normal actions of insulin. Specifically, as a result of changes in their surface receptors, cells are unable to use insulin as effectively and beta cells in the pancreas increase their production of insulin which in turn leads to hyperglycemia. Insulin resistance is generally associated with Type 2 diabetes.

As discussed herein, the treatment group fed MSPrebiotic® Resistant Potato Starch demonstrated a reduction in insulin resistance of 54% as estimated by HOMA-IR compared to the control group.

Accordingly, in one embodiment of the invention, there is provided a method of decreasing insulin resistance in an individual in need of such treatment comprising administering to said individual an effective amount of resistant potato starch. Preferably, the resistant potato starch is MSPrebiotic® Resistant Potato Starch.

As will be appreciated by one of skill in the art, the decrease in insulin resistance in the individual may be in comparison to insulin resistance in said individual prior to beginning administration or treatment. Alternatively, the decrease may be in comparison to an untreated control of similar age and condition. As will be appreciated by one of skill in the art, the control does not necessarily need to be repeated every time.

In yet another embodiment of the invention, there is provided use of MSPrebiotic® Resistant Potato Starch in the preparation of a medicament for treating type 2 diabetes in an individual in need of such treatment.

As discussed herein, these results indicate that resistant potato starch, for example, MSPrebiotic® Resistant Potato Starch is an effective dietary supplement offering protection against multiple metabolic risk factors that are associated with cardiovascular disease and diabetes.

According to one embodiment of the invention, there is provided a method of increasing High Density Lipoprotein plasma levels in an individual in need of such treatment comprising administering to said individual 0.25 grams to 40 grams of MSPrebiotic® Resistant Potato Starch daily.

According to one embodiment of the invention, there is provided a method of decreasing blood glucose levels in an individual in need of such treatment comprising administering to said individual 0.25 grams to 40 grams of MSPrebiotic® Resistant Potato Starch daily.

According to one embodiment of the invention, there is provided a method of decreasing insulin resistance in an individual in need of such treatment comprising administering to said individual 0.25 grams to 40 grams of MSPrebiotic® Resistant Potato Starch daily.

For example, in these embodiments, an individual in need, of such treatment may be an individual with increased insulin resistance, for example an individual with Type 2 diabetes or a person with a familial history of Type 2 diabetes or a person at risk of developing Type 2 diabetes.

Yet further, in the above embodiments, “daily” does not necessarily mean “every day” but may mean 70%, 80%, 90% or more of days within a given month or other suitable time period. As will be appreciated by one of skill in the art, many suitable products for administering resistant potato starch such as MSPrebiotic® Resistant Potato Starch can be developed and are within the scope of the invention, for example, a capsule in the nutraceutical industry as well as alternative food and/or beverage options that would more readily allow daily RS intakes in an effective amount, for example, as discussed herein.

It is of note that as discussed herein, although no statistically significant difference was observed between HDL-C concentrations, RS consumption increased HDL lipoprotein levels. For illustrative purposes, the lipoprotein can be referred to as the ‘boat’ while the HDL-C itself is the ‘cargo’.

The invention will now be explained and illustrated by way of examples. However, the invention is not necessarily limited to the examples.

The pre-clinical assessment included the following metabolic parameters in response to dietary supplementation of MSPrebiotic® Resistant Starch capsules for 30 days:

1. Standard fasting assessment of lipid biomarkers of cardiovascular disease risk including blood total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides (TAG).

2. Detailed fasting analysis of lipoprotein distribution patterns including very low-density lipoprotein (VLDL), LDL, and HDL particle number and size.

3. Blood glucose, insulin, and estimation of insulin resistance using homeostatic model assessment (HOMA).

Animals

All animals remained healthy throughout the course of the experiment. No difference was observed in food intake or body weight gain (FIG. 1) between the placebo and RS animals. The pigs readily consumed the capsules when mixed into the morning and evening powdered ration. For two pigs (one placebo, one RS) it was necessary to break open the capsules and feed the resistant potato starch as a free powder mixed in with the meal.

Blood Lipid and Lipoprotein Response

We observed no difference (p<0.05) in standard fasting lipid biomarkers of cardiovascular disease risk between the placebo and RS-fed pigs (FIG. 2). Although some studies have observed reductions in blood lipids in response to RS consumption, the majority of previous studies suggest that blood lipid responses to RS consumption are highly variable and dependent on the type and amount of RS and subject specific factors including gender and baseline lipid levels [4, 5].

As we are not aware of any previous studies examining lipoprotein distribution patterns in response to resistant starch consumption, this endpoint, which is that the MSPrebiotic® Resistant Potato Starch is effective in reducing biomarkers of cardiovascular disease and diabetes, specifically, lipoprotein levels and glucose, is a surprising discovery, as discussed herein.

Although traditional cholesterol tests [LDL (bad) and HDL (good) cholesterol)] are the standard indicators of cardiovascular disease risk, a large majority of individuals who have suffered a heart attack have ‘normal’ cholesterol levels. As it is the lipoproteins that are responsible for carrying cholesterol throughout the body, analysis of lipoprotein particle number and size can provide a more in depth and accurate level of risk analysis. Although VLDL and LDL particle number and size was not different (p<0.05) between the placebo and MSPrebiotic® Resistant Potato Starch groups (FIGS. 7, 8, 9, Appendix), total HDL particle number was increased by 28% (p<0.05) in response to MSPrebiotic® Resistant Potato Starch pigs versus placebo pigs (FIG. 3). An elevated number of HDL lipoprotein particles is considered to be inherently heart healthy as the major function of these lipoproteins is to remove excess cholesterol from peripheral tissues to the liver for removal from the body in a process called ‘reverse cholesterol transport’. These results indicate that MSPrebiotic® Resistant Potato Starch is an effective cardioprotective supplement to reduce cardiovascular disease risk by elevating the number of HDL lipoprotein particles.

Blood Glucose and Insulin

We observed an 11% reduction (p<0.05) in blood glucose following MSPrebiotic® Resistant Potato Starch compared with the placebo capsule group (FIG. 4). Similarly, supplementation of MSPrebiotic® Resistant Potato Starch resulted in a numerical reduction in both blood insulin (−31%, p=0.4, FIG. 5,) and HOMA-IR (−54%, p=0.14, FIG. 6). HOMA-IR is a method to estimate insulin resistance using fasting blood glucose and insulin concentrations. These results suggest that MSPrebiotic® Resistant Starch is an effective dietary supplement to manage blood sugar within a healthy range.

Implications and Future Opportunities

The results of this pre-clinical evaluation indicate that dietary supplementation of MSPrebiotic® Resistant Potato Starch capsules at a controlled dose of for example 10 g/d is an effective strategy to favorably modulate multiple markers of metabolic syndrome including blood glucose and insulin, as well as HDL particle number.

Experimental Approach

Twelve 8-week old male Yorkshire pigs were purchased from Michael Fanning Farms (Howe, Ind.) and treated in accordance with Institutional Animal Care and Use Committee approved guidelines. Pigs were housed individually in an environmentally controlled room at 20° C. in research pens fitted with single feeders and drinking nipples within the Animal Care Facility at the University at Buffalo. The animals were allowed free access to water for the duration of the experiment. Animals were fed a grower pig diet for 1 week for acclimation to the surroundings and animal care staff. Following acclimatization, all animals were placed on a high fat/high cholesterol diet meant to reflect standard North American nutrient intakes (Teklad Custom Research Diet, TD.10520, TABLE 1). On day 1 of the experimental period, animals (n=6) were randomly divided into two dietary groups: 1) a placebo group supplemented with capsules containing normal gelatinized starch; and 2) a RS group supplemented with RS capsules containing MSPrebiotic® Resistant Potato Starch. Capsules were prepared at the Richardson Centre for Functional Foods and Nutraceuticals, University of Manitoba, as discussed below. As the capsules were formulated to contain ˜0.32 g of RS, each animal received ˜31 capsules/d mixed in with the morning and evening meals to reach a target RS intake of 10 g/d. Composition of the gelatinized and MSPrebiotic® Resistant Potato Starch is presented in Table 2.

On day 1 of the experimental period each pig was weighed and a fasting blood sample (˜5 mls) was obtained from the ear vein into sodium heparin tubes while the pigs were sedated with an intramuscular injection of a swine premix solution [Telazol (100 mg/ml) at 4.4-6 mg/kg and xylazine (100 mg/ml) at 2.2 mg/kg].

This blood sample was used as a baseline for all endpoint blood measures. The pigs were fed their respective test diets at a level of roughly 5.5% of their body weight for the duration of the experiment. Feed intake was monitored on a daily basis while body weights were taken at weekly intervals. On d-30 of the experimental period following an 8-hour overnight fast, the pigs were weighed, sedated with an intramuscular injection of a swine premix solution and subsequently anesthetized with isoflurane (2.5%) in O2 (gas flow rate at 2.5 L/min) for blood collection by cardiac puncture. Following exsanguination, the animals were euthanized by overdose of isoflurane.

Endpoint Analysis:

Plasma total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and TAG were determined by automated enzymatic kits on a Pentra 400 autoanalyzer (Kamiya Biomedical Company, Seattle, Wash., USA). Direct assessment of lipoprotein particle number and size was conducted by nuclear magnetic resonance spectroscopy (Liposcience, Raleigh, N.C.). Serum insulin was analysed by ELISA (EZRMI-13K, Millipore, Billerica, Mass.) and glucose was measured by colorimetric analysis (ab6533, abcam, Cambridge, Mass.). Insulin resistance was estimated by homeostatic model assessment (HOMA-IR). Blood C-reactive protein (CRP) as measured by ELISA (Ser. No. 10/011,236, Cayman Chemical).

Statistical Analysis

Data were analyzed with a general linear model ANOVA using experimental block as a fixed factor. Data were analyzed with SPSS 16 for Mac (SPSS Inc, Chicago Ill.). Data are presented as mean±SEM. All results are the means from 6 animals. Differences were considered significant at p≦0.05.

Accordingly, the inventors then proceeded to investigate the development of pharmaceutical products.

As discussed herein, considerable care must be taken to ensure that as much of the resistant starch is retained as possible. As discussed below, the inventors have discovered that there are several additional considerations beyond maintaining a temperature below 60° C. when preparing pharmaceutical products such as tablets and capsules from resistant starch such as moisture content of the starch and pressure used in tablet formation.

Initially, the inventors attempted to develop resistant starch-containing capsules. However, initial attempts were unsuccessful as the resistant starch tended to clump together and was difficult to fill or flow into a suitably sized capsule. It was subsequently discovered that carefully drying the resistant starch to a moisture content of below 20% for example between 12-19% produced flowable starch that did not stick together. In other embodiments, the moisture content may be below 17%, for example, 12-17% or 12-15%.

Accordingly, in one embodiment of the invention, there is provided a method of preparing a resistant starch capsule comprising drying a quantity of resistant starch to below 20%, for example, below 17% and then flowing the dried resistant starch into a capsule. Specifically, the moisture content may be 12-19%, 12-17% or 12-15%.

The inventors also attempted to prepare resistant starch tablets as there were concerns that the resistant starch capsules may not have been the ideal delivery mechanism due to slow release of the resistant starch from the capsule.

In these embodiments, solution of a suitable excipient is prepared and resistant starch is added to the solution. The mixture is then allowed to form into pellets or granules. The granules are dried and then reduced in size using any suitable means known in the art. The resistant starch material is formed into a tablet under a suitable pressure. Surprisingly, it was found that pressures typically used for tablet preparation, for example 200-500 MPa in the preparation of such tablets fractured the granule structure of the resistant starch, thereby greatly reducing the quantity of resistant starch in the tablet. Subsequent experimentation showed that pressures between 60-100 MPa is suitable to produce the tablet, while lower pressures produced tablets which broke apart and higher pressures fractured the granule structure of the resistant starch to an unacceptable degree.

In some embodiments, the excipient is a binder, for example, polyvinylpyrrolidone (PVP). Surprisingly, while other binders such as methylcellulose, gelatinized starch and hydroxypropylcelluose were tested, it was discovered that only PVP produced tablets having the desired properties.

In some embodiments, the pharmaceutical composition is prepared as follows: an aqueous solution of 1 part PVP is prepared. 9 parts resistant starch is dissolved therein at a temperature below 60° C. Pellets and granules are allowed to form which are then dried. The dried material is reduced in size with a hammer mill. The material is then formed into a tablet and subjected to a pressure between for example 45-100 MPa or in some preferred embodiments between 60-100 MPa.

As will be appreciated by one of skill in the art, the capsules and tablets may be made in any suitable size, for example, in a unit dosage to be taken once per day, or in dosages to be taken multiple times per day, for example twice or more per day on a suitable dosage regimen or schedule. For example, a suitable dosage regimen may be one or more capsules or tablets comprising 50-750 mg resistant starch prepared as discussed herein every 2, 4, 6, 8, 12 or 24 hours or taken with meals.

For example, the capsules or tablets may be 50 mg, 100 mg, 200 mg, 220 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 600 mg, 700 mg, 750 mg or any suitable similar size according to patient and/or consumer preference.

In some embodiments, each capsule may weigh 625±5.0 mg and each capsule may contain 528±17.6 mg of material of which 350-370 mg is resistant starch.

In some embodiments, the material is formed into tablets at a pressure between 45-100 MPa or between 60-100 MPa. In some embodiments, each tablet is 40-50% resistant starch, for example, 45% resistant starch.

In one embodiment of the invention, there is provided a method of preparing a resistant starch pharmaceutical composition comprising mixing an effective amount of resistant starch with a suitable excipient. The excipient may be PVP. The mixture may be 1 part PVP to 9 parts resistant starch or resistant starch source. In some embodiments, the pharmaceutical composition is in the form of a tablet. In other embodiments, resistant starch is dried to a moisture content below 20% for example between 12-19% or below 17% for example between 12-17% and flowed into a suitably sized capsule, thereby producing a resistant starch capsule.

As will be readily apparent to one of skill in the art, “an effective amount” will depend on the animal, its age, weight and general condition, among other factors. However, as discussed above, the inventors have discovered that a much lower level of resistant starch than previously believed is sufficient to treat or otherwise ameliorate at least one of the symptoms associated with infectious diarrhea, post-weaning diarrhea and/or gastrointestinal stresses associated with weaning such as fecal consistency, daily food intake and the like. For example, in some embodiments, the “effective amount” is resistant starch at approximately 0.1%-2.5%, 0.1-2.0%, 0.1-1.5%, 0.1-1.0%, 0.2-2.5%, 0.2-2.0%, 0.2-1.5%, 0.2-1.0%, 0.3-2.5%. 0.3-2.0%, 0.3-1.5%, 0.3-1.0%, 0.4-2.5%. 0.4-2.0%, 0.4-1.5%, 0.4-1.0%, 0.5-2.5%. 0.5-2.0%, 0.5-1.5%, or 0.5-1.0% of the animal's diet.

In other embodiments, the “effective amount” may be a resistant starch capsule or tablet. The resistant starch capsule or tablet may be prepared according to the methods described herein. Preferably, the resistant starch capsule is a 500 mg capsule. The tablet may be a 220 mg tablet or a 250 mg tablet.

Preparation of Resistant Starch Tablets

Formulation: 90% resistant starch+10% PVP, the water should be 30% of the total amount of the flour. For example, 9 kg resistant starch plus 1 kg PVP, the water should be 10×30%=3 kg (3 liter).

Procedure

Step 1: Resistant starch, PVP, and water are weighed respectively.

Step 2: Dissolve the PVP into water, heat and dissolve it.

Step 3: Cool down the PVP solution in ice water bath into room temperature.

Step 4: Add the PVP solution, into Resistant starch powders and mix thoroughly with a mixer (10-20 min depending on the amount).

Step 5: Screening the damp mass through a mesh to form pellets or granules with a granulator.

Step 6: Drying the granules by using a dryer in 40-45° C. for about 72 h, depending on the amount of the granules prepared.

Step 7: After the granules are dried, they are passed through a hammer mill (We use #4 screen, with 0.75 mm diameter holes).

Step 8: Go through the tablet machine (Pressure of 60-100 MPa is required for the resistant starch which contains 60-75% RS. Higher RS requires higher pressure. The final tablet product should contain about 40% RS, db).

While the preferred embodiments of the invention have been described above, it will be recognized and understood that various modifications may be made therein, and the appended claims are intended to cover all such modifications which may fall within the spirit and scope of the invention.

TABLE 1

Ingredient
g · kg

Casein
214.0

DL-Methionine
2.5

Sucrose
300.0

Maltodextrin
215.7

Lard
150.0

Cholesterol
15.0

Cellulose
25.8

Vitamin Mix, AIN-93-VX(94047)
15.0

Choline Bitartrate
4.5

TBHQ, antioxidant
0.01

Calcium Phosphate, dibasic
20.0

Calcium Carbonate
8.9

Potassium Citrate, monohydrate
12.84

Other
15.58

Nutrient composition (% energy)

Carbohydrates
49.5

Protein
18.0

Fat
32.5

Table 2 Characterization of Starches Used in the Feeding Study

Gelatinized starch
MSPrebiotic

Item
(placebo)
Potato Starch

Resistant starch (%)
0
60

Total starch per capsule (g)
0.44
0.53

Resistant starch (g/capsule)
0
0.32

Readily available starch (g)
0.44
0.21

Group Means and Statistical Analysis

Group statistics

diet
N
Mean
Std. Deviation
Std. Error Mean

VLOLP
1.00
6
14.0167
7.01331
2.86317

2.00
5
10.1860
7.41435
3.31580

LOLP
1.00
6
687.9400
121.58705
49.63770

2.00
6
750.7967
225.26834
91.96541

HOLP
1.00
6
50.6000
11.19202
4.56912

2.00
5
64.8920
5.73582
2.56514

VLOLsize
1.00
6
48.4850
5.96435
2.43494

2.00
6
52.7917
5.32634
2.17447

LDLsize
1.00
6
24.9750
.02881
.01176

2.00
6
24.9767
.04761
.01944

HOLsize
1.00
6
8.1717
.34067
.13908

2.00
6
7.9583
.15211
.06210

CalTAG
1.00
6
33.3383
9.35784
3.82032

2.00
5
38.3740
9.79292
4.37953

CalVLOTAG
1.00
6
13.6800
7.80738
3.18735

2.00
6
16.5080
6.59142
2.94777

CalHOLC
1.00
6
56.5300
12.33928
5.03749

2.00
5
55.6150
10.82422
4.41897

Glucose
1.00
6
114.0000
23.15167
9.45163

2.00
5
89.6000
25.74490
11.51347

Insulin
1.00
6
11.8333
10.68095
4.36048

2.00
6
8.1600
1.67720
.75007

totalC
1.00
6
209.1667
33.33117
13.60739

2.00
6
225.0000
33.38263
13.62840

HOLC
1.00
6
58.3333
14.54189
5.93670

2.00
6
54.6667
7.03325
2.87131

LOldirect
1.00
6
201.5000
32.07959
13.09644

2.00
6
248.6667
72.18495
29.46938

LOlbase
1.00
4
40.5000
29.03446
14.51723

2.00
3
51.0000
12.49000
7.21110

LOlchange
1.00
4
235.1025
171.84862
85.92431

2.00
3
399.8700
73.56742
42.47417

Glucosebase
1.00
4
86.7500
58.32881
29.16440

2.00
3
140.0000
18.02776
10.40833

Glucosechange
1.00
4
8.3025
12.19190
6.09595

2.00
3
−24.8567
17.94504
10.36057

Insulinbase
1.00
4
10.7750
10.02576
5.01288

2.00
3
21.5333
21.07637
12.16845

Insulinchange
1.00
4
−2.1525
51.99271
25.99636

2.00
3
−36.5333
48.98915
28.28390

HOMAIR
1.00
5
3.6560
2.73476
1.22302

2.00
5
1.6780
.45598
.20392

t-test or equality of means

Levene's test for equality of variances

95% confidence interval of the difference

Equivariances
F
Sig
t
df
Sig (2-tailed)
Mean difference
Std.error difference
upper
lower

VLDLP
Assumed
160
698
879
9
.402
3.83067
4.3S637
−6.02414
13.68S47

Not assumed

874
8.437
.406
3.83067
4.38090
−6.18144
13.84277

LDLP
Assumed
3.402
.095
−.601
10
561
−62.85667
104.50617
−295.71092
169.99758

Not assumed

−.601
7.685
565
−62.85667
104.50617
−305.57672
179.86338

HDLP
Assumed
3.599
.090
−2.572
9
.030
−14.29200
5.55676
−26.86227
−1.72173

Not assumed

−2.728
7.693
.027
−14.29200
5.23993
−26.45969
−2.12431

VLDLsize
Assumed
165
694
−1.319
10
217
−4.30667
3.26454
−11.58052
2.96719

Not assumed

−1.319
9.875
217
−4.30667
3.26454
−11.59305
2.97972

LDLsize
Assumed
396
543
−.073
10
.943
−.00167
.02272
−.05229
.04895

Not assumed

−.073
8.229
.943
−.00167
.02272
−.05380
.05047

HDLsize
Assumed
4.246
.066
1.401
10
.192
.21333
.15231
−.12604
.55271

Not assumed

1.401
6.917
.205
.21333
.15231
−.14770
.57437

CalTAG
Assumed
.009
.925
−.870
9
.407
−5.03567
5.78502
−18.12230
8.05097

Not assumed

−.866
8.477
.410
−5.03567
5.81164
−18.30721
8.23588

CalVLDLTAG
Assumed
.987
.346
−.640
9
.538
−2.82800
4.41555
−12.81666
7.16066

Not assumed

−.651
8.990
.531
−2.82800
4.34150
−12.65081
6.99481

calHDLC
Assumed
.413
.535
.137
10
.894
.91500
6.70101
−14.01579
15.84579

Not assumed

.137
9.833
.894
.91500
6.70101
−14.05020
15.88020

Glucose
Assumed
.038
.849
1.656
9
132
24.40000
14.73761
−8.93878
57.73878

Not assumed

1.638
8.221
139
24.40000
14.89608
−9.79036
58.59036

insulin
Assumed
4.764
.057
.755
9
.470
3.67333
4.86801
−7.33886
14.68553

Not assumed

.830
5.294
.442
3.67333
4.42452
−7.51260
14.85926

totalC
Assumed
.169
.689
−.822
10
.430
−15.83333
19.25862
−58.74421
27.07755

Not assumed

−.822
10.000
.430
−15.83333
19.25862
−58.74423
27.07756

HDLC
Assumed
1.107
.318
.556
10
.590
3.66667
6.59461
−11.02704
18.36037

Not assumed

.556
7.218
.595
3.66667
6.59461
−11.83220
19.16553

LDLdirect
Assumed
5.198
.046
−1.463
10
.174
−47.16667
32.24843
−119.02064
24.68731

Not assumed

−1.463
6.901
.188
−47.16667
32.24843
−123.64476
29.31143

LDLbase
Assumed
1.430
.285
−.577
5
.589
−10.50000
18.20577
−57.29942
36.29942

Not assumed

−.648
4.273
.550
−10.50000
16.20957
−54.39384
33.39384

Independent Samples Test

t-test for Equality of Menns

Levene's

Test for Equality

of Variances

Sig.
Mean
Std. Error

F
Sig.
t
df
(2-tailed)
Difference
Difference

VLDLP
Equalvariances
.160
.698
.879
9
.402
3.83067
4.35637

assumed

Equalvariances

.874
3.437
.406
3.83067
4.35090

not assumed

LDLP
Equalvariances
3.402
.095
−.601
10
.561
−62.85667
104.50617

assumed

Equalvariances

−.601
7.685
.545
−62.85667
104.50617

not assumed

HDLP
Equalvariances
3.599
.090
−2.572
9
.030
−14.29200
5.55676

assumed

Equalvariances

−2.728
7.693
.027
−14.29200
5.23993

not assumed

VLDLsize
Equalvariances
.165
.694
−1.319
10
.217
−4.30667
3.26454

assumed

Equalvariances

−1.319
9.875
.217
−4.30667
3.26454

not assumed

LDLsize
Equalvariances
.396
.543
−.073
10
.943
−.00167
.02272

assumed

Equalvariances

−.073
8.229
.943
−.00167
.02272

not assumed

HDLsize
Equalvariances
4.246
.066
1.401
10
.192
2.1333
.15231

assumed

Equalvariances

1.401
6.917
.205
2.1333
.15231

not assumed

calTAG
Equalvariances
.009
.925
−.870
9
.407
−5.03567
5.78502

assumed

Equalvariances

−.566
8.477
.410
−5.03567
5.51164

not assumed

CalVLDLTAG
Equalvariances
.987
.346
−.640
9
.538
−2.82800
4.41555

assumed

Equalvariances

−.651
8.990
.531
−2.82800
4.34150

not assumed

calHDLC
Equalvariances
.413
.535
.137
10
.894
.91500
6.70101

assumed

Equalvariances

.137
9.533
.894
.91500
6.70101

not assumed

glucose
Equalvariances
.038
.849
1.656
9
.132
24.4 text missing or illegible when filed

14.73761

assumed

Equalvariances

1.638
8.221
.139
2 4.4 text missing or illegible when filed

14.89608

not assumed

insulin
Equalvariances
4.764
.057
.755
9
.470
3.67333
4.86801

assumed

Equalvariances

.830
8.294
.442
3.67333
4.42452

not assumed

totalC
Equalvariances
.169
.689
−.822
10
.430
−15.83333
19.25862

assumed

Equalvariances

−.822
10.000
.430
−15.83333
19.25862

not assumed

HDLC
Equalvariances
1.107
.318
.556
10
.590
3.66667
6.59461

assumed

Equalvariances

.556
7.218
.595
3.66667
6.59461

not assumed

LDLdirect
Equalvariances
5.198
.046
−1.463
10
.174
−47.16667
32.24843

assumed

Equalvariances

−1.463
6.901
.188
−47.16667
32.24843

not assumed

LDLbase
Equalvariances
1.430
.285
−.577
5
.589
−10.50000
18.20577

assumed

Equalvariances

−.648
4.273
.550
−10.50000
16.20957

not assumed

LDLchange
Equalvariances
1.695
.250
−1.530
5
.187
−164.76750
107.09875

assumed

Equalvariances

−1.719
4.263
.156
−164.76750
95.84906

not assumed

glucosebase
Equalvariances
2.765
.157
−1.496
5
.195
−53.25000
35.58962

assumed

Equalvariances

−1.720
3.722
.166
−53.25000
30.96604

not assumed

glucosechange
Equalvariances
.887
.389
2.941
5
.032
33.15917
11.27670

assumed

Equalvariances

2.758
3.356
.062
33.15917
12.02090

not assumed

insulinbase
Equalvariances
4.399
.090
−.913
5
.403
−10.75833
11.78263

assumed

Equalvariances

−.817
2.685
.480
−10.75833
13.16055

not assumed

insulinchange
Equalvariances
.000
.999
.886
5
.416
34.38083
38.80876

assumed

Equalvariances

.895
4.612
.415
34.38083
35.41601

not assumed

HOMAIR
Equalvariances
5.905
.041
1.595
8
.149
1.97800
1.23991

assumed

Equalvariances

1.595
4.222
.182
1.97800
1.23991

not assumed

t-test for

Equality

of Menns

95%

Confidence Interval

of the Difference

Lower
Upper

VLDLP
Equalvariances
−6.02414
13.68547

assumed

Equalvariances
−6.18144
13.84277

not assumed

LDLP
Equalvariances
−295.71092
169.99758

assumed

Equalvariances
−305.57672
179.86338

not assumed

HDLP
Equalvariances
−26.86227
−1.72173

assumed

Equalvariances
−26.45969
−2.12431

not assumed

VLDLsize
Equalvariances
−11.58052
2.96719

assumed

Equalvariances
−11.59305
2.97972

not assumed

LDLsize
Equalvariances
−.05229
.04895

assumed

Equalvariances
−.05380
.05047

not assumed

HDLsize
Equalvariances
−.12604
.55271

assumed

Equalvariances
−.14770
.57437

not assumed

calTAG
Equalvariances
−18.12230
8.05097

assumed

Equalvariances
−18.30721
8.23588

not assumed

CalVLDLTAG
Equalvariances
−12.81666
7.16066

assumed

Equalvariances
−12.65081
6.99481

not assumed

calHDLC
Equalvariances
−14.01579
15.84579

assumed

Equalvariances
−14.05020
15.88020

not assumed

glucose
Equalvariances
−8.93878
57.73878

assumed

Equalvariances
−9.79036
53.59036

not assumed

insulin
Equalvariances
−7.33886
14.68553

assumed

Equalvariances
−7.51260
14.85926

not assumed

totalC
Equalvariances
−58.74421
27.07755

assumed

Equalvariances
−58.74423
27.07756

not assumed

HDLC
Equalvariances
−11.02704
18.36037

assumed

Equalvariances
−11.83220
19.16553

not assumed

LDLdirect
Equalvariances
−119.02064
24.68731

assumed

Equalvariances
−123.64476
29.31143

not assumed

LDLbase
Equalvariances
−57.29942
36.29942

assumed

Equalvariances
−54.39384
33.39384

not assumed

LDLchange
Equalvariances
−441.61595
112.08095

assumed

Equalvariances
−124.52671
94.99171

not assumed

glucosebase
Equalvariances
−144.73602
38.23602

assumed

Equalvariances
−141.51528
35.31528

not assumed

glucosechange
Equalvariances
−1.17150
62.14684

assumed

Equalvariances
−2.89877
59.21711

not assumed

insulinbase
Equalvariances
−41.04654
19.52988

assumed

Equalvariances
−55.56406
34.04739

not assumed

insulinchange
Equalvariances
−65.38026
134.14193

assumed

Equalvariances
−66.92160
135.68327

not assumed

HOMAIR
Equalvariances
−.88123
1.83723

assumed

Equalvariances
−1.39424
5.35024

not assumed

text missing or illegible when filed

indicates data missing or illegible when filed

REFERENCES

1. Robertson M D: Dietary-resistant starch and glucose metabolism. Curr Opin Clin Nutr Metab Care 2012, 15(4):362-367.

2. Aller E E, Abete I, Astrup A, Martinez J A, van Baak M A: Starches, sugars and obesity.

Nutrients 2011, 3(3):341-369.

3. Bhandari S K, Nyachoti C M, Krause D O: Raw potato starch in weaned pig diets and its influence on postweaning scours and the molecular microbial ecology of the digestive tract. J Anim Sci 2009, 87(3):984-993.

4. Kendall C W, Emam A, Augustin L S, Jenkins D J: Resistant starches and health. J AOAC Int

2004, 87(3):769-774.

5. Rideout T C: Getting personal: considering variable interindividual responsiveness to dietary lipid-lowering therapies. Curr Opin Lipidol 2011, 22(1):37-42.

6. Rideout, T C et al. Nutrient utilisation and intestinal fermentation are differentially affected by the consumption of resistant starch varieties and conventional fibres in pigs. British Journal of Nutrition 2008, 99:984-992.

Improvement of Blood Lipids, Glucose Tolerance and Insulin Sensitivity

Information

Publication Number

Date Filed

Date Published

Inventors

Original Assignees

CPC

International Classifications

Abstract

Description

Claims

PRIOR APPLICATION INFORMATION

PCT Information

Provisional Applications (1)